Pipothiazine palmitate in the management of aggressive mentally handicapped patients.
The efficacy of intramuscular pipothiazine palmitate (PP) in the management of aggressive mentally handicapped patients was examined in a double-blind, placebo-controlled, cross-over study, in which 30 patients received each treatment for 13 weeks. A target symptom scale of aggressiveness (TSA) and a clinical global impression scale of efficacy were rated at monthly intervals, and an extra-pyramidal side-effects scale weekly. The patients showed marked improvement during treatment with PP, which was assessed as superior to placebo. Individual and total TSA scores were also reduced compared to placebo.
Lynch
D M
DM
Eliatamby
C L
CL
Anderson
A A
AA
D000328:Adult; D000374:Aggression / Q000187:drug effects*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000097:blood / Q000188:drug therapy / Q000523:psychology*; D008297:Male; D008875:Middle Aged; D010640:Phenothiazines; D013843:Thiazines / Q000627:therapeutic use*; D014508:Urea / Q000097:blood
D014150:Antipsychotic Agents; D010640:Phenothiazines; D013843:Thiazines; D014508:Urea